1 recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Recruiting 1 |
Follow Ju Dong Yang: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| IIT2025-03-YANG-LIFT-HCC STRIDE Regimen (Tremelimumab 300 mg AND Durvalumab 1500 mg) combined with LRT (TACE, TARE, or RFA) - Hepato Cellular Carcinoma | Phase 2 | Recruiting | Ju Dong Yang | 41 | 2026-04-01 | 2026-03-27 |
durvalumab (1) · tremelimumab (1)
United States (1)